Literature DB >> 22645050

Tumor-associated macrophages in pediatric classical Hodgkin lymphoma: association with Epstein-Barr virus, lymphocyte subsets, and prognostic impact.

Mário Henrique M Barros1, Rocio Hassan, Gerald Niedobitek.   

Abstract

PURPOSE: Tumor-infiltrating macrophages are associated with adverse outcome in adult classical Hodgkin lymphoma (cHL). We have previously shown age-related changes in the lymphocyte composition of pediatric cHL. We therefore hypothesized that the number, function, and prognostic impact of macrophages in pediatric cHL would be different from adult cases. EXPERIMENTAL
DESIGN: We analyzed the number of macrophages and dendritic cells (DC) in the tumor microenvironment of pediatric cHL by immunohistochemistry. Results were analyzed in context of age, histologic characteristics, Epstein-Barr virus (EBV) status, clinical follow-up, and our previous study of T-cell populations in these cases.
RESULTS: One hundred cHL cases were studied, including 69% nodular sclerosis and 23% mixed cellularity cases. A total of 44.8% of cases were EBV-positive. Patients ≤10 years displayed more CD14(+) cells (P = 0.025). In comparison with nodular sclerosis, mixed cellularity was characterized by higher numbers of CD14(+), (P = 0.003) and CD163(+) cells (P = 0.027). EBV(+) cases exhibited higher numbers of CD14(+) (P < 0.0005), CD68(+) (P = 0.005), and CD163(+) cells (P = 0.02). CD68-positive cells did not display an effect on outcome. Worse overall survival was observed in cases with CD163/CD8 ratio ≥2 (P = 0.007). High numbers of CD163(+) cells were associated with worse progression-free survival (PFS; P = 0.015). Furthermore, high numbers of CD163(+) and granzyme B(+) cells were associated with worse PFS in EBV-negative (P = 0.005) but not in EBV-positive cases.
CONCLUSION: Our results suggest that macrophage composition in pediatric cHL is distinct from adults. Functional status of macrophages and their value as prognostic indicators in pediatric cHL may depend on EBV status.

Entities:  

Mesh:

Year:  2012        PMID: 22645050     DOI: 10.1158/1078-0432.CCR-12-0129

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  29 in total

1.  The interplay between local immune response and Epstein-Barr virus-infected tonsillar cells could lead to viral infection control.

Authors:  Aldana G Vistarop; Melina Cohen; Fuad Huaman; Lucia Irazu; Marcelo Rodriguez; Elena De Matteo; María Victoria Preciado; Paola A Chabay
Journal:  Med Microbiol Immunol       Date:  2018-07-25       Impact factor: 3.402

Review 2.  Immunotherapy in pediatric malignancies: current status and future perspectives.

Authors:  Christian M Capitini; Mario Otto; Kenneth B DeSantes; Paul M Sondel
Journal:  Future Oncol       Date:  2014       Impact factor: 3.404

Review 3.  Novel Immunotherapies for T Cell Lymphoma and Leukemia.

Authors:  Paola Ghione; Alison J Moskowitz; Nadia E K De Paola; Steven M Horwitz; Marco Ruella
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

4.  A gene expression-based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma.

Authors:  Rebecca L Johnston; Anja Mottok; Fong Chun Chan; Aixiang Jiang; Arjan Diepstra; Lydia Visser; Adèle Telenius; Randy D Gascoyne; Debra L Friedman; Cindy L Schwartz; Kara M Kelly; David W Scott; Terzah M Horton; Christian Steidl
Journal:  Blood       Date:  2022-02-10       Impact factor: 25.476

5.  Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial.

Authors:  Jennifer A Kanakry; Hailun Li; Lan L Gellert; M Victor Lemas; Wen-son Hsieh; Fangxin Hong; King L Tan; Randy D Gascoyne; Leo I Gordon; Richard I Fisher; Nancy L Bartlett; Patrick Stiff; Bruce D Cheson; Ranjana Advani; Thomas P Miller; Brad S Kahl; Sandra J Horning; Richard F Ambinder
Journal:  Blood       Date:  2013-02-05       Impact factor: 22.113

Review 6.  Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine.

Authors:  Ruifang Sun; L Jeffrey Medeiros; Ken H Young
Journal:  Mod Pathol       Date:  2016-08-01       Impact factor: 7.842

7.  Flow cytometry for assessment of the tumor microenvironment in pediatric Hodgkin lymphoma.

Authors:  Meret Henry; Steven Buck; Süreyya Savaşan
Journal:  Pediatr Blood Cancer       Date:  2018-07-15       Impact factor: 3.167

Review 8.  How do viruses trick B cells into becoming lymphomas?

Authors:  Ethel Cesarman
Journal:  Curr Opin Hematol       Date:  2014-07       Impact factor: 3.284

9.  Difference in the hypoxic immunosuppressive microenvironment of patients with neurofibromatosis type 2 schwannomas and sporadic schwannomas.

Authors:  Ryota Tamura; Yukina Morimoto; Mizuto Sato; Yuki Kuranari; Yumiko Oishi; Kenzo Kosugi; Kazunari Yoshida; Masahiro Toda
Journal:  J Neurooncol       Date:  2020-01-03       Impact factor: 4.130

10.  Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma.

Authors:  Ann-Kathrin Desch; Kristin Hartung; Ante Botzen; Alexander Brobeil; Mathias Rummel; Lars Kurch; Thomas Georgi; Theresa Jox; Stefan Bielack; Stefan Burdach; Carl Friedrich Classen; Alexander Claviez; Klaus-Michael Debatin; Martin Ebinger; Angelika Eggert; Jörg Faber; Christian Flotho; Michael Frühwald; Norbert Graf; Norbert Jorch; Udo Kontny; Christof Kramm; Andreas Kulozik; Joachim Kühr; Karl-Walter Sykora; Markus Metzler; Hermann L Müller; Michaela Nathrath; Thomas Nüßlein; Michael Paulussen; Arnulf Pekrun; Dirk Reinhardt; Harald Reinhard; Claudia Rössig; Axel Sauerbrey; Paul-Gerhardt Schlegel; Dominik T Schneider; Wolfram Scheurlen; Lothar Schweigerer; Thorsten Simon; Meinolf Suttorp; Peter Vorwerk; Roland Schmitz; Regine Kluge; Christine Mauz-Körholz; Dieter Körholz; Stefan Gattenlöhner; Andreas Bräuninger
Journal:  Leukemia       Date:  2019-08-20       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.